


Cohort A1 (HS): 70 mg IV Q4Wx3 (N=6)
Cohort A2 (HS): 210 mg IV Q4Wx3 (N=3-6)
Cohort A3 (HS): 420 mg IV Q4Wx3 (N=5-6)
Cohort A4 (HS): 210 mg SC Q4Wx3 (N=5-6)
Cohort A5 (HS): 700 mg IV Q4Wx3 (N=4-6)
Mean (SD) Serum AMG 139/MEDI2070 Concentration (µg/mL)
1000
100
10
1
0.1
0.01
0
28
56
84
112
140
168
196
224
252
Time after First Dose (day)

Figure 1


Subject 1
Subject 2
CDAI Score
300
250
200
150
100
50
0
-28
0
28
56
84
112
140
168
196
224
252
Time after First Dose (day)



Subject 1
Subject 2
CDAI Score Change from Day -1 (Baseline)
150
100
50
0
-50
-100
-150
0
28
56
84
112
140
168
196
224
252
Time after First Dose (day)

Figure 2




Intravenous dose
Subcutaneous dose
k_a
Central Compartment Cp, V
k_{el}
k_{12}
k_{21}
Peripheral Compartment Vp

Figure 3


7 mg SC
Serum AMG 139 (µg/mL)
10^3
10^0
10^-3
0
50
100
150
Nominal Time (day)




21 mg SC
Serum AMG 139 (µg/mL)
10^3
10^0
10^-3
0
50
100
150
Nominal Time (day)

FIGURE 4







FIGURE 4 Continued...






FIGURE 4 Continued…




FIGURE 4 Continued...




Figure 5



CL (L/day)
0.10
0.15
0.20
0.25
0.30
0.35
60
70
80
90
100
Body Weight (kg)
Vc (L)
2
3
4
5
6
60
70
80
90
100
Body Weight (kg)

Figure 6

V_H1 (SEQ ID NO: 1)

QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNEYYADSVKGR

CDR 1 CDR 2

FTISRDNSKNTLYLQMNSLRAEDTAVYYCARDRGYTSSWYPDAFDIWGQGTMVTVSS

CDR 3

V_L1 (SEQ ID NO: 2)

QSVLTQPPSVSGAPGQRVTISCTGSSSNTGAGYDVHWYQQVPGTAPKLLIYGSGNRPS

CDR 1 CDR 2

GVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSSLSGWVFGGGTRLTVL

CDR 3

Figure 7